About Phenex Pharmaceuticals Ag
Phenex Pharmaceuticals Ag is a Limited Liability Partnership company and was incorporated on Oct 15, 2019 in Germany. Its corporate identification number is (CIN) HRB734710 and its current status is Active.
Key Metrics
CIN
HRB734710
Current Status
Active
Entity Type
Limited Liability Partnership
Date Of Incorporation
Oct 15, 2019
Latest Employee Count
21 as on Dec 31, 2020
Brands associated with Phenex Pharmaceuticals Ag
There is one brand associated with Phenex Pharmaceuticals Ag which include Phenex Pharma .
Name | Short Description | Founded Year | Location | Current Stage |
|---|---|---|---|---|
Developer of small molecules targeting nuclear receptors for the treatment of liver diseases & autoimmune diseases | 2002 | Public |
Financials of Phenex Pharmaceuticals Ag
Competitors & Alternates of Phenex Pharmaceuticals Ag
Phenex Pharma is the only brand associated with Phenex Pharmaceuticals Ag, and here are its Top 10 competitors ranked by Tracxn score:
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
5th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
6th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
7th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
8th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 | |
9th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
10th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 68/100 | |
139th | Phenex Pharma 2002, Ludwigshafen (Germany), Public | Developer of small molecules targeting nuclear receptors for the treatment of liver diseases & autoimmune diseases | $24.5M | 43/100 |
News related to Phenex Pharmaceuticals Ag
•
•
•
•
•
Phenex Pharmaceuticals AG Receives 100M Milestone Payment From GileadBioSpace•Jan 05, 2017•Phenex Pharma
•
Phenex Raises €6M in Series C Financing |FinSMEsFinSMEs•Sep 21, 2010•Phenex Pharma, CD-Venture, Creathor Venture, Kfw and 3 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Attribution:
Auszug aus dem Unternehmensregister July 24, 2026
FAQs about Phenex Pharmaceuticals Ag
Explore our recently published Legal Entities
